Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Disease progression in multiple system atrophy (MSA) and Parkinson’s disease (PD) shows marked patient-to-patient heterogeneity. We hypothesize that machine learning methods applied to multimodal MRI ...

Multiple system atrophy (MSA) is a neurodegenerative disease characterized by cerebellar ataxia, parkinsonism, and autonomic dysfunction 1. Patients with MSA experience rapid disease progression, ...

In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified In mUMSARS scores and MRI-based brain volume ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Alterity Therapeutics Limited ATHE stock is up during Tuesday’s session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its ...

Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

A new MRI marker showed high accuracy for progressive supranuclear palsy diagnosis across international cohorts. Find out more.